Pantarhei Bioscience (sinds 2001) werd in 2014 uitgebreid met een succesvolle Oncology-tak en diende in de afgelopen jaren meer dan 220 patenten in. Een actieve onderneming, volop in ontwikkeling -niet voor niets Panta Rhei – alles stroomt- met een diepgewortelde missie en visie: “Pantarhei ontwikkelt veilige en effectieve nieuwe geneesmiddelen op basis van bestaande menselijke moleculen tot en met “proof-of-concept” bij de mens. Met deze strategie zijn we 18 jaar geleden begonnen en is succesvol gebleken,” aldus de nieuwe CEO Yvette Zimmerman. Lees hier het artikel.

Contribution of Pantarhei Oncology to the 18th World Congress of the International Academy of the Human Reproduction (IAHR), April 3-6, 2019 in Dublin by an invited lecture of Herjan Coelingh Bennink

On Thursday April 4, 2019, a key lecture entitled “Estrogens, Estetrol and Breast Cancer” was given by Herjan Coelingh Bennink, President of Pantarhei Oncology during a scientific session “Oncology, Breast and Gynecological Surgery”. The session was chaired by by Andrea Genazzani. For more information, please read the abstract.

 

Gedeon Richter Plc. and Pantarhei Bioscience BV today announced that they have entered into a license and supply agreement to commercialise Pantarhei’s combined oral contraceptive (COC), containing 30 µg ethinyl estradiol, 150 µg levonorgestrel and 50 mg dehydroepiandrosterone (DHEA). The product is under development with successfully completed Phase II trials and is ready for further clinical studies to obtain marketing approval. The geographic scope of the agreement covers Europe, Russia, Latin America and Australia.

Read more: Press Release GedeonRichter – Pantarhei February 4, 2019

Pantarhei Bioscience, the Dutch biopharmaceutical company, is pleased to announce the appointment of Yvette Zimmerman as Chief Executive Officer (CEO), with effect from January 2019. The founder of Pantarhei Herjan Coelingh Bennink speaks proudly about his successor: “Yvette is a very experienced drug developer and driven by what is really important for people and scientifically sound.”

During the 18 years of its existence, Pantarhei has filed more than 220 patents. Initially Pantarhei developed new medicines for Women’s Health. Following the foundation of the subsidiary company Pantarhei Oncology in 2014, the focus has been redirected to new treatment concepts for endocrine cancer, especially breast and prostate cancer.

Read more: Press Release New CEO Pantarhei Bioscience

Pantarhei Oncology rapporteert positieve resultaten van de behandeling van borstkanker met het zwangerschapshormoon Estetrol.

Persbericht Pantarhei Oncology 6 december 2018